Fig. 1
GNIP1 is highly expressed in NSCLC and predicts a poor clinical outcome. A The mRNA expression distribution of GNIP1 in N0 stage and N1-3 stage NSCLC tissues, N represents the stages of lymph node metastasis. B The mRNA expression distribution of GNIP1 in NSCLC tissues with different pathological stages. C Analysis of GNIP1 mRNA expression, survival time and survival status in TCGA data set. The patient samples were divided into high-expression group and low-expression group according to the median value of GNP1 mRNA expression. The upper panel was the scatter diagram of the mRNA expression of GNIP1, different colors represent different expression groups. The middle panel was the scatter diagram distribution of survival time and survival state corresponding to the expression of different sample GNIP1. The lower panel represents a heat map of the GNIP1 mRNA expression (All X-axis represents the NSCLC patient samples distribution). The GNIP1 expression analysis was produced by pheatmap package (R version, 3.6.2, pheatmap version, 1.0.8). D The relationship between the mRNA expression of GNIP1 and the possibility of survival in NSCLC patients. E Receiver operating characteristic curve analysis of GNIP1 at different time, in which the higher the AUC value, the stronger the predictive ability of survival conditions. AUC, area under the curve. F Western blot to check the protein levels of GNIP1 in NSCLC cells and normal lung epithelial cells (BEAS-2B) (upper panel). Quantitative gray value analysis of GNIP1 expression (lower panel). Data are presented as the average of three independent experiments (mean ± SD). *, p < 0.05, **, p < 0.01, ***, p < 0.001. G Western blot detected the expression of GNIP1 in tissues of 8 patients with non-small cell lung cancer. C: cancer tissues; N: normal tissues